Table 1.
Baseline Study Population Characteristics by HIV Status
| Factor | Total Cohort (N=127) | HIV-Infected Arm (n=63) | HIV-Uninfected Arm (n=64) | p-value1 |
|---|---|---|---|---|
| Demographics | ||||
| Age, median (IQR) years | 35 (28, 42) | 36 (26, 45) | 35 (28,40) | 0.44 |
| Gender, N (%) male | 115 (91%) | 58 (92%) | 57 (89%) | 0.76 |
| Ethnicity, N (%) | 0.11 | |||
| Caucasian | 75 (59%) | 33 (52%) | 42 (66%) | |
| African American | 32 (25%) | 21 (33%) | 11 (17%) | |
| Other | 20 (16%) | 9 (14%) | 11 (17%) | |
| Clinical History | ||||
| BMI, median (IQR) kg/m2 | 27 (24, 29) | 26 (24, 29) | 27 (24, 28) | 0.86 |
| Current cigarette use, N (%) | 23 (18%) | 14 (22%) | 9 (14%) | 0.26 |
| History of influenza infection (self-reported), N (%) | 17 (13%) | 10 (16%) | 7 (11%) | 0.45 |
| Receipt of 2009–2010 seasonal influenza vaccine, N (%) | 121 (95%) | 58 (92%) | 63 (98%) | 0.12 |
| Type of 2009–2010 seasonal vaccine | <0.01 | |||
| Inactivated, N (%) | 103 (85%) | 57 (98%) | 46 (73%) | |
| Live, N (%) | 18 (15%) | 1 (2%) | 17 (27%) | |
| Number of seasonal influenza vaccines in past 3 years | <0.01 | |||
| <3 | 39 (31%) | 28 (44%) | 11 (17%) | |
| 3 | 88 (69%) | 35 (56%) | 53 (83%) | |
| Number of other household members | <0.01 | |||
| 0 | 35 (28%) | 24 (38%) | 11 (17%) | |
| 1 | 35 (28%) | 20 (32%) | 15 (23%) | |
| ≥2 | 57 (45%) | 19 (30%) | 38 (59%) | |
| Number of school-attendees in household | <0.01 | |||
| 0 | 85 (67%) | 53 (84%) | 32 (50%) | |
| ≥1 | 42 (33%) | 10 (16%) | 32 (50%) | |
| HIV History | ||||
| HIV duration, median (IQR) years | --- | 7.1 (2.0, 13.7) | --- | --- |
| CDC Stage, N (%) | --- | --- | --- | |
| A | 47 (75%) | |||
| B | 11 (17%) | |||
| C | 5 (8%) | |||
| Nadir CD4 cell count, median (IQR) cells/mm3 | --- | 299 (214, 434) | --- | --- |
| Nadir categories, N (%) | ||||
| <200 | --- | 12 (19%) | --- | --- |
| 200–349 | 26 (41%) | |||
| ≥350 | 25 (40%) | |||
| CD4 cell count at vaccination, median (IQR) cells/mm3 | --- | 595 (476, 819) | --- | --- |
| CD4 categories, N (%) | ||||
| <350 | --- | 6 (10%) | --- | --- |
| 350–499 | 14 (22%) | |||
| 500–749 | 23 (37%) | |||
| ≥750 | 20 (32%) | |||
| Plasma HIV RNA at vaccination, median (IQR) log10 copies/ml | --- | 1.7 (1.7, 2.4) | --- | --- |
| Plasma HIV RNA <50 copies/ml, N (%) | --- | 36 (57%) | --- | --- |
| Currently taking HAART, N (%) | --- | 52 (83%) | --- | --- |
1
Comparison of the HIV-infected and -uninfected subjects, from two-sample t-test or Fisher’s exact test, as appropriate
BMI, body mass index; GMT, geometric mean titer; HAART, highly active antiretroviral therapy; IQR, interquartile range; N, number